GILD vs IBRX
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. IBRX: ImmunityBio develops innovative immunotherapies and cell-based cancer vaccines that leverage its Cancer BioShield platform to treat oncology and infectious disease patients.
Side-by-side fundamentals
| Metric | GILD | IBRX | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $135.77 | $7.60 | |
| Market cap as of 2026-08-12 | $168.3B | $8.1B | |
| P/E as of 2026-08-12 | 19.42 | n/a | |
| PEG as of 2026-08-12 | 2.53 | -0.08 | IBRX lower |
| Net margin as of 2026-08-12 | -10.6% | -598.6% | GILD higher |
| Gross margin as of 2026-08-12 | +79.6% | +99.3% | IBRX higher |
| Operating margin as of 2026-08-12 | -8.2% | -151.9% | GILD higher |
| ROE as of 2026-08-12 | -16.3% | -193.3% | GILD higher |
| ROA as of 2026-08-12 | -5.8% | -172.9% | GILD higher |
| Debt / equity as of 2026-08-12 | 2.22 | 0.00 | IBRX lower |
| Revenue growth (YoY) as of 2026-08-12 | +5.5% | +192.9% | IBRX higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | +678.6% | IBRX higher |
| Dividend yield as of 2026-08-12 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-12 | 0.33 | 0.07 | |
| 1-year return as of 2026-08-11 close | +12.7% | +207.7% | IBRX higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.